Clinical Trials Browser

Leukemia, Biphenotypic, Acute × venetoclax × 1 year × Clear all

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

153 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1 Recruiting

30 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

235 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Phase 2 Active not recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06177067 2026-03-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Recruiting

24 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase 1 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Active not recruiting

37 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05901974 2025-12-16

Venetoclax Combined With Azactidine in the Treatment of ALAL

Phase 2 Recruiting

23 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute

NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Phase 1/2 Terminated

24 enrolled 15 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04797767 2025-10-15

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1/2 Recruiting

62 enrolled

Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT07012447 2025-06-10

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

Phase 2 Recruiting

32 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Pyloric Stenosis, Hypertrophic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Completed

150 enrolled 17 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic